pioglitazone has been researched along with Movement Disorders in 3 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Movement Disorders: Syndromes which feature DYSKINESIAS as a cardinal manifestation of the disease process. Included in this category are degenerative, hereditary, post-infectious, medication-induced, post-inflammatory, and post-traumatic conditions.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Chronic administration of pioglitazone could contract this effect of BDL on event frequency and interevent interval, though the difference with the sham group was still significant in the duration of action potential." | 1.43 | Alterations in the intrinsic electrophysiological properties of Purkinje neurons in a rat model of hepatic encephalopathy: Relative preventing effect of PPARγ agonist. ( Aghaei, I; Dehpour, A; Haghani, M; Hajali, V; Shabani, M; Sheibani, V, 2016) |
| " Oral dyskinesia was induced by chronic administration of haloperidol (1 mg/kg i." | 1.39 | Possible beneficial effect of peroxisome proliferator-activated receptor (PPAR)--α and γ agonist against a rat model of oral dyskinesia. ( Budhiraja, RD; Grover, S; Kumar, P; Singh, K; Vikram, V, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Grover, S | 1 |
| Kumar, P | 1 |
| Singh, K | 1 |
| Vikram, V | 1 |
| Budhiraja, RD | 1 |
| Aghaei, I | 2 |
| Shabani, M | 2 |
| Doustar, N | 1 |
| Nazeri, M | 1 |
| Dehpour, A | 2 |
| Hajali, V | 1 |
| Haghani, M | 1 |
| Sheibani, V | 1 |
3 other studies available for pioglitazone and Movement Disorders
| Article | Year |
|---|---|
Possible beneficial effect of peroxisome proliferator-activated receptor (PPAR)--α and γ agonist against a rat model of oral dyskinesia.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Body Weight; Disease Models, Animal; Fenofibrate; H | 2013 |
Peroxisome proliferator-activated receptor-γ activation attenuates motor and cognition impairments induced by bile duct ligation in a rat model of hepatic cirrhosis.
Topics: Animals; Avoidance Learning; Bile Duct Diseases; Bile Ducts; Cognition Disorders; Hypoglycemic Agent | 2014 |
Alterations in the intrinsic electrophysiological properties of Purkinje neurons in a rat model of hepatic encephalopathy: Relative preventing effect of PPARγ agonist.
Topics: Action Potentials; Animals; Biophysics; Disease Models, Animal; Electric Stimulation; Hepatic Enceph | 2016 |